Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure.
Jebbink M, van Werkhoven E, Mandjes IA, Wesseling J, Lips EH, Vrancken Peeters MJ, Loo CE, Sonke GS, Linn SC, Falo Zamora C, Rodenhuis S. Jebbink M, et al. Among authors: vrancken peeters mj. Breast Cancer Res Treat. 2015 Aug;153(1):145-52. doi: 10.1007/s10549-015-3510-4. Epub 2015 Jul 26. Breast Cancer Res Treat. 2015. PMID: 26210520
Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer.
Rigter LS, Loo CE, Linn SC, Sonke GS, van Werkhoven E, Lips EH, Warnars HA, Doll PK, Bruining A, Mandjes IA, Vrancken Peeters MJ, Wesseling J, Gilhuijs KG, Rodenhuis S. Rigter LS, et al. Among authors: vrancken peeters mj. Br J Cancer. 2013 Dec 10;109(12):2965-72. doi: 10.1038/bjc.2013.661. Epub 2013 Oct 22. Br J Cancer. 2013. PMID: 24149178 Free PMC article.
Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study.
van Ommen-Nijhof A, Steenbruggen TG, Wiersma TG, Balduzzi S, Daletzakis A, Holtkamp MJ, Delfos M, Schot M, Beelen K, Siemerink EJM, Heijns J, Mandjes IA, Wesseling J, Rosenberg EH, Vrancken Peeters MJT, Linn SC, Sonke GS. van Ommen-Nijhof A, et al. Among authors: vrancken peeters mjt. Eur J Cancer. 2024 Oct 20;213:115083. doi: 10.1016/j.ejca.2024.115083. Online ahead of print. Eur J Cancer. 2024. PMID: 39489924
Neoadjuvant chemotherapy for radiation associated angiosarcoma (RAAS) of the breast: A retrospective single center study.
van der Burg SJC, Reijers SJM, Kuijpers A, Heimans L, Scholten AN, Haas RLM, Boven HV, Kolff WM, Vrancken Peeters MTFD, Kerst M, Seinstra BA, Steeghs N, van der Graaf WTA, Schrage YM, van Houdt WJ. van der Burg SJC, et al. Breast. 2024 Oct 21;78:103825. doi: 10.1016/j.breast.2024.103825. Online ahead of print. Breast. 2024. PMID: 39476458 Free article.
Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines.
Groheux D, Vaz SC, Poortmans P, Mann RM, Ulaner GA, Cook GJR, Hindié E, Pilkington Woll JP, Jacene H, Rubio IT, Vrancken Peeters MJ, Dibble EH, de Geus-Oei LF, Graff SL, Cardoso F. Groheux D, et al. Among authors: vrancken peeters mj. Breast. 2024 Sep 12;78:103806. doi: 10.1016/j.breast.2024.103806. Online ahead of print. Breast. 2024. PMID: 39303572 Free PMC article. Review.
124 results